Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
The Form 144 filing indicates that an insider, Michael Y. Chi, plans to sell up to 2,100 Class A shares of Hims & Hers Health, Inc. (HIMS) through Fidelity Brokerage on or about 24 Jul 2025. At the prevailing price used in the form, the proposed sale is valued at $120,792. With 215,453,899 Class A shares outstanding, the transaction represents roughly 0.001 % of the public float.
Chi acquired the shares via an employee stock option granted 24 Feb 2022 and exercised for cash on 24 Jul 2025. The filing also discloses prior insider activity:
- 5100 shares sold 06 Jun 2025 for $285,600
- 5400 shares sold 10 Jun 2025 for $307,800
- 17,102 shares sold 17 Jun 2025 for $1,021,844.50
- 13,750 shares sold 23 Jul 2025 for $770,000
The notice affirms the seller is not aware of undisclosed adverse information. While continued insider selling may warrant monitoring, the volume remains immaterial relative to the company’s capitalization and is unlikely to affect trading dynamics on its own.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company’s 215,453,899 shares outstanding, implying minimal dilution or governance impact.
The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.
Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.
Hims & Hers Health (HIMS) has filed a Form 144 disclosing CEO Andrew Dudum’s intention to sell up to 125,335 Class A shares (≈ $6.21 million) through Fidelity Brokerage on or after 21 Jul 2025. The proposed block equals 0.06 % of the 215.5 million shares outstanding.
The notice also lists prior insider activity: entities tied to Dudum disposed of ≈ 463,000 shares between 28 Apr and 16 Jul 2025, generating roughly $26.9 million in gross proceeds. Individual sales ranged from 2,792 to 128,127 shares.
No operational or financial metrics accompany the filing; Form 144 only signals planned insider sales. Although the volume is small relative to float, continued CEO selling can pressure sentiment. Investors may watch for additional filings, confirmation of a 10b5-1 plan, or further ownership changes.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Soleil Boughton has filed a Form 144 indicating an intent to sell 2,572 Class A shares through Fidelity Brokerage Services on or about 14 July 2025. The shares have an aggregate market value of $122,993.04 and account for roughly 0.001% of the company’s 215.45 million shares outstanding, suggesting a limited impact on the public float.
The shares were acquired via restricted-stock vesting on 15 June 2025 and are being disposed of as compensation-related stock. The filer has also disclosed seven prior open-market sales in the past three months totaling 23,535 shares for ~$1.15 million in gross proceeds.
Because Form 144 is a notice of proposed sale, the transaction may or may not be executed, and it does not automatically imply negative operational information. Nonetheless, the continued pattern of insider selling can influence investor perception.